Board Directors
Nick is an experienced CEO with over 20 years’experience in public listed and private companies operating internationally across the life sciences, healthcare diagnostic and biotechnology industries. Prior to joining Biofortuna, Nick was CEO of Source BioScience plc, the laboratory service and products business, where he helped grow revenues five fold, delivering an enterprise valued at more than £70 million. Nick holds a PhD in Mycology and is a Chartered Accountant, qualifying with KPMG. Nick is currently Chairman of Epistem Limited, the pre-clinical and clinical development CRO.
Nick is an experienced Chief Operating Officer in the life sciences and healthcare diagnostic sectors. Prior to joining Biofortuna, Nick was COO of Source BioScience plc for ten years, expanding the operations from a single site in the UK to ten facilities worldwide, integrating multiple acquisitions. Before Source BioScience, Nick was a co-founder of the genomics services and products company Geneservice and worked for over ten years in complex genetics and genomics; initially at Oxford University and then for the MRC at the Wellcome Trust Sanger Centre. Nick qualified as a microbiologist and worked in the NHS, completing a PhD on the molecular methods used to characterise outbreaks of bacterial meningitis.
Mark is a serial supporter of growth companies with a wealth of experience of start-up and early stage businesses. He is a director of a number of health and life science companies, whose technologies range from oncology therapeutic development through to medical devices for a range of applications including the management of metabolic disease.
Simon has over 30 years experience in biotech working for Amersham International (now GE), ICI and AstraZeneca. Previously he was CEO of the life science company Tepnel plc (now Hologic) and Chief Executive of start-up company DNA Research Innovations Ltd (DRI) which was acquired by Invitrogen Corporation. More recently Simon was the Executive Chairman of Lab901 Ltd which was acquired by Agilent Technologies Inc and is currently the Chairman of AIM listed Fusion Antibodies plc, an antibody engineering services provider.
Geoff is a Fellow of the Institute of Chartered Accountants in England and Wales having qualified with PricewaterhouseCoopers and is a Chartered Tax Adviser. Geoff is an experienced Finance Director who has served on the Boards of numerous PE backed and AIM listed businesses across a wide range of sectors including healthcare, drug testing services, IT, medical testing services, manufacturing of emergency services equipment and biotech companies.
David Turner joined Foresight Group in 2018 and currently works as a Senior Investment Manager in the London office. He has over 14 years of experience. David is responsible for originating and executing new private equity investments. Prior to joining Foresight David worked at Stage Capital as an Investment Director where he focussed on making private equity investments in Europe. He has also worked as Corporate Development Manager at Experian plc, focussing on executing new investments globally for the group.
David holds a Masters Degree in Mechanical Engineering from Nottingham University and is a chartered accountant, having qualified with Grant Thornton in 2007.
Biofortuna Limited © 2019 |